newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Devdiscourse
Innovent Biologics and Pfizer have entered a groundbreaking partnership, valued at $10.5 billion.
Innovent Biologics and Pfizer signed a $10.5 billion partnership to develop 12 cancer drugs.
KEY POINTS
Pfizer will pay Innovent $650 million upfront, with potential for further milestone-based payments.
The agreement focuses on early-stage oncology drugs and leverages China's growing biotech capabilities.
This deal marks a new scale of collaboration between Western and Asian pharmaceutical companies.
Innovent Biologics and Pfizer have entered a groundbreaking partnership, valued at $10.5 billion, to develop a dozen early-stage cancer drugs. This strategic move capitalizes on China's thriving biotech industry.
The agreement includes an upfront payment of $650 million to Innovent and anticipates additional payments based on developmental milestones.
This deal reflects a global push among pharmaceutical giants to leverage the rapidly expanding biotech sector in Asia, highlighting an increasing collaboration between Western and Asian drug developers.
(With inputs from agencies.)